drugset / Trial / NCT02218294

Study to Determine How BCX4161 is Metabolized and Eliminated by the Body

NCT02218294 ↗

Phase 1 Completed 7 enrolled BioCryst Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the extent that radioactive dose of BCX4161 taken by mouth ends up in the urine, feces and expired air. If there are metabolites of BCX4161 made by the body, the chemical composition of these metabolites and their profile over time in blood and urine will be determined.

Timeline

Start
2014-08
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject avoralstat Small molecule — Oral

Indications